Conference Call with Strides Pharma Science Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Strides Pharma Science announced Q1FY26 results Revenue at Rs 11,197 million, grew 6.2% YoY Absolute gross margin at Rs 6,755 million, grew 11.7% YoY Gross margin improved to 60.3%, up 300 bps YoY EBITDA grew 14.8% YoY to Rs 2,181 million with EBITDA margin at 19.5%, grew 150 bps YoY US revenue at $71 million, grew 7.0% YoY Operational PAT at Rs 1,140 million, Grew 80.6% YoY Operational EPS at Rs 12.4 Reported PAT at Rs 1,056 million. Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5%, an increase of 150 bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of Rs 12.4. Consequently, ROCE stands at 15.1% for Q1. The company will enhance its R&D; efforts during the year to drive sustainable long-term growth.” Result PDF